- Email: [email protected]
Unlabeled uses of commercial products or investigational uses not yet approved
SEMINARS IN ONCOLOGY NURSING The Epidermal Growth Factor Receptor as a Novel Target for Cancer Therapy Unlabeled Uses of Commercial Products or Investigational Uses Not Yet Approved R a t i o n a l e for the Epidermal Growth Factor R e c e p t o r as a T a r g e t f o r C a n c e r T h e r a p y , L a u r a S. Wood IMC-C225, ABX-EGF, ZD1839, OSI-774, PKI166, CI-1033, and ERB-569 have not b e e n approved by the FDA alone or in c o m b i n a t i o n with c h e m o t h e r a p y for the t r e a t m e n t of malignant tumors.
NOTICE ABOUT OFF-LABEL USE PRESENTATIONS IIESE PROCEEDINGS m a y include articles on drugs or devices, or uses of drugs or devices, that have not b e e n approved by the US Food and Drug Administration (FDA) or have b e e n approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to d e t e r m i n e the FDA clearance status of each drug or devices he or she wishes to use in clinical practice. The C e n t e r for Biomedical C o n t i n u i n g Education is c o m m i t t e d to the free e x c h a n g e of nursing e d u c a t i o n . I n c l u s i o n of a n y p r e s e n t a t i o n in this p r o g r a m , including p r e s e n t a t i o n s on offlabel uses, does not i m p l y an e n d o r s e m e n t by T h e C e n t e r for B i o m e d i c a l C o n t i n u i n g Education of the uses, p r o d u c t s , or t e c h n i q u e s presented. For additional information about approved uses, c h e c k the package labeling or consult the Physic i a n s ' Desk Rqfercnee.
T
The E p i d e r m a l G r o w t h F a c t o r R e c e p t o r as a Novel T a r g e t for C a n c e r T h e r a p y : Case Studies a n d Clinical Implications, Riddle et ctl 1MC-C225, ZD1839, and OSI-774 have not b e e n approved by the FDA alone or in c o m b i n a t i o n with c h e m o t h e r a p y for t r e a t m e n t of n o n - s m a l l cell lung c a n c e r and othcr malignant tumors. Overview of Clinical Trials With E p i d e r m a l G r o w t h F a c t o r R e c e p t o r I n h i b i t o r s in A d v a n c e d N o n - S m a l l Cell l,ung Cancer, Melodic Tlm'mas ZD1839, OSI-774, IMC-C225, ABX-EGF, PKI166, GW21)16, and CI-1033 have not been approved bv the FDA alone or in c o m b i n a t i o n with c h e m o t h e r a p y for t r e a t m e n t of n o n - s m a l l cell lung c a n c e r and other malignant tumors.
35
NOTICE ABOUT OFF-LABEL USE PRESENTATIONS IIESE PROCEEDINGS m a y include articles on drugs or devices, or uses of drugs or devices, that have not b e e n approved by the US Food and Drug Administration (FDA) or have b e e n approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to d e t e r m i n e the FDA clearance status of each drug or devices he or she wishes to use in clinical practice. The C e n t e r for Biomedical C o n t i n u i n g Education is c o m m i t t e d to the free e x c h a n g e of nursing e d u c a t i o n . I n c l u s i o n of a n y p r e s e n t a t i o n in this p r o g r a m , including p r e s e n t a t i o n s on offlabel uses, does not i m p l y an e n d o r s e m e n t by T h e C e n t e r for B i o m e d i c a l C o n t i n u i n g Education of the uses, p r o d u c t s , or t e c h n i q u e s presented. For additional information about approved uses, c h e c k the package labeling or consult the Physic i a n s ' Desk Rqfercnee.
T
The E p i d e r m a l G r o w t h F a c t o r R e c e p t o r as a Novel T a r g e t for C a n c e r T h e r a p y : Case Studies a n d Clinical Implications, Riddle et ctl 1MC-C225, ZD1839, and OSI-774 have not b e e n approved by the FDA alone or in c o m b i n a t i o n with c h e m o t h e r a p y for t r e a t m e n t of n o n - s m a l l cell lung c a n c e r and othcr malignant tumors. Overview of Clinical Trials With E p i d e r m a l G r o w t h F a c t o r R e c e p t o r I n h i b i t o r s in A d v a n c e d N o n - S m a l l Cell l,ung Cancer, Melodic Tlm'mas ZD1839, OSI-774, IMC-C225, ABX-EGF, PKI166, GW21)16, and CI-1033 have not been approved bv the FDA alone or in c o m b i n a t i o n with c h e m o t h e r a p y for t r e a t m e n t of n o n - s m a l l cell lung c a n c e r and other malignant tumors.
35